{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:43:55Z","timestamp":1780638235265,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T00:00:00Z","timestamp":1250640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1471-2334-9-131","type":"journal-article","created":{"date-parts":[[2009,8,19]],"date-time":"2009-08-19T18:13:38Z","timestamp":1250705618000},"source":"Crossref","is-referenced-by-count":14,"title":["Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days)"],"prefix":"10.1186","volume":"9","author":[{"given":"Cees","family":"van Nieuwkoop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan W","family":"van't Wout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem JJ","family":"Assendelft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk W","family":"Elzevier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane MS","family":"Leyten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Koster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Hanke","family":"Wattel-Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie M","family":"Delfos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C","family":"Ablij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed J","family":"Kuijper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Pander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanet W","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida C","family":"Spelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap T","family":"van Dissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,8,19]]},"reference":[{"key":"896_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/S0735-6757(97)90087-5","volume":"15","author":"AG Pinson","year":"1997","unstructured":"Pinson AG, Philbrick JT, Lindbeck GH, Schorling JB: Fever in the clinical diagnosis of acute pyelonephritis. Am J Emerg Med. 1997, 15: 148-151. 10.1016\/S0735-6757(97)90087-5.","journal-title":"Am J Emerg Med"},{"issue":"Suppl 1","key":"896_CR2","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/j.ijantimicag.2006.05.017","volume":"28","author":"GB Piccoli","year":"2006","unstructured":"Piccoli GB, Consiglio V, Colla L, Mesiano P, Magnano A, Burdese M, Marcuccio C, Mezza E, Veglio V, Picolli G: Antibiotic treatment for acute 'uncomplicated' or 'primary' pyelonephritis: a systematic, 'semantic revision'. Int J Antimicrob Agents. 2006, 28 (Suppl 1): S49-S63. 10.1016\/j.ijantimicag.2006.05.017.","journal-title":"Int J Antimicrob Agents"},{"key":"896_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2165\/00019053-200523110-00005","volume":"23","author":"P Brown","year":"2005","unstructured":"Brown P, Ki M, Foxman B: Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy. Pharmacoeconomics. 2005, 23: 1123-1142. 10.2165\/00019053-200523110-00005.","journal-title":"Pharmacoeconomics"},{"key":"896_CR4","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/clinids\/22.6.1051","volume":"22","author":"LE Nicolle","year":"1996","unstructured":"Nicolle LE, Friesen D, Harding GK, Roos LL: Hospitalization for acute pyelonephritis in Manitoba, Canada, during the period from 1989 to 1992; impact of diabetes, pregnancy, and aboriginal origin. Clin Infect Dis. 1996, 22: 1051-1056.","journal-title":"Clin Infect Dis"},{"key":"896_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S1047-2797(02)00272-7","volume":"13","author":"B Foxman","year":"2003","unstructured":"Foxman B, Klemstine KL, Brown PD: Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. Ann Epidemiol. 2003, 13: 144-150. 10.1016\/S1047-2797(02)00272-7.","journal-title":"Ann Epidemiol"},{"key":"896_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/519268","volume":"45","author":"CA Czaja","year":"2007","unstructured":"Czaja CA, Scholes D, Hooton TM, Stamm WE: Population-Based Epidemiologic Analysis of Acute Pyelonephritis. Clin Infect Dis. 2007, 45: 273-280. 10.1086\/519268.","journal-title":"Clin Infect Dis"},{"key":"896_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/0003-4819-106-3-341","volume":"106","author":"WE Stamm","year":"1987","unstructured":"Stamm WE, McKevitt M, Counts GW: Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. A randomized trial. Ann Intern Med. 1987, 106: 341-345.","journal-title":"Ann Intern Med"},{"key":"896_CR8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1001\/archinte.159.1.53","volume":"159","author":"G Mombelli","year":"1999","unstructured":"Mombelli G, Pezzoli R, Pinoja-Lutz G, Monotti R, Marone C, Franciolli M: Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial. Arch Intern Med. 1999, 159: 53-58. 10.1001\/archinte.159.1.53.","journal-title":"Arch Intern Med"},{"key":"896_CR9","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","volume":"283","author":"DA Talan","year":"2000","unstructured":"Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, Reuning-Scherer J, Church DA: Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA. 2000, 283: 1583-1590. 10.1001\/jama.283.12.1583.","journal-title":"JAMA"},{"key":"896_CR10","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1185\/030079907X233340","volume":"23","author":"HA Klausner","year":"2007","unstructured":"Klausner HA, Brown P, Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB: A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and\/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin. 2007, 23: 2637-2645. 10.1185\/030079907X233340.","journal-title":"Curr Med Res Opin"},{"key":"896_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1086\/520427","volume":"29","author":"JW Warren","year":"1999","unstructured":"Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE: Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999, 29: 745-758. 10.1086\/520427.","journal-title":"Clin Infect Dis"},{"key":"896_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0891-5520(03)00004-7","volume":"17","author":"TM Hooton","year":"2003","unstructured":"Hooton TM: The current management strategies for community-acquired urinary tract infection. Infect Dis Clin North Am. 2003, 17: 303-332. 10.1016\/S0891-5520(03)00004-7.","journal-title":"Infect Dis Clin North Am"},{"key":"896_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0891-5520(03)00012-6","volume":"17","author":"JN Rubenstein","year":"2003","unstructured":"Rubenstein JN, Schaeffer AJ: Managing complicated urinary tract infections: the urologic view. Infect Dis Clin North Am. 2003, 17: 333-351. 10.1016\/S0891-5520(03)00012-6.","journal-title":"Infect Dis Clin North Am"},{"key":"896_CR14","first-page":"933","volume":"71","author":"K Ramakrishnan","year":"2005","unstructured":"Ramakrishnan K, Scheid DC: Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician. 2005, 71: 933-942.","journal-title":"Am Fam Physician"},{"key":"896_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ijantimicag.2007.07.040","volume":"31","author":"LE Nicolle","year":"2008","unstructured":"Nicolle LE: Short-term therapy for urinary tract infection: success and failure. International Journal of Antimicrobial Agents. 2008, 31: 40-45. 10.1016\/j.ijantimicag.2007.07.040.","journal-title":"International Journal of Antimicrobial Agents"},{"key":"896_CR16","doi-asserted-by":"crossref","unstructured":"ACOG Practice Bulletin No. 91: Treatment of urinary tract infections in nonpregnant women. Obstet Gynecol. 2008, 111: 785-794.","DOI":"10.1097\/AOG.0b013e318169f6ef"},{"key":"896_CR17","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1345\/aph.1K347","volume":"41","author":"AJ Mehlhorn","year":"2007","unstructured":"Mehlhorn AJ, Brown DA: Safety concerns with fluoroquinolones. Ann Pharmacother. 2007, 41: 1859-1866. 10.1345\/aph.1K347.","journal-title":"Ann Pharmacother"},{"key":"896_CR18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1185\/030079907X188099","volume":"23","author":"PB Iannini","year":"2007","unstructured":"Iannini PB: The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Curr Med Res Opin. 2007, 23: 1403-1413. 10.1185\/030079907X188099.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"896_CR19","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1093\/clind\/15.Supplement_1.S216","volume":"15","author":"RH Rubin","year":"1992","unstructured":"Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE: Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis. 1992, 15 (Suppl 1): S216-27. S216-S227.","journal-title":"Clin Infect Dis"},{"key":"896_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0924-8579(99)00014-X","volume":"11","author":"KG Naber","year":"1999","unstructured":"Naber KG: Experience with the new guidelines on evaluation of new anti-infective drugs for the treatment of urinary tract infections. Int J Antimicrob Agents. 1999, 11: 189-196. 10.1016\/S0924-8579(99)00014-X.","journal-title":"Int J Antimicrob Agents"},{"key":"896_CR21","volume-title":"47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","author":"C van Nieuwkoop","year":"2007","unstructured":"van Nieuwkoop C, van't Wout JW, Spelt I, Numan-Ruberg SC, H\u00e4cker EL, van Dissel JT: Treatment of febrile urinary tract infection in the elderly and male at primary care and emergency department. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 2007, Abstract L-497."},{"key":"896_CR22","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/sim.1425","volume":"22","author":"RB D'Agostino Sr","year":"2003","unstructured":"D'Agostino RB, Massaro JM, Sullivan LM: Non-inferiority trials: design concepts and issues \u2013 the encounters of academic consultants in statistics. Stat Med. 2003, 22: 169-186. 10.1002\/sim.1425.","journal-title":"Stat Med"},{"key":"896_CR23","doi-asserted-by":"publisher","first-page":"a2390","DOI":"10.1136\/bmj.a2390","volume":"337","author":"M Zwarenstein","year":"2008","unstructured":"Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D: Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008, 337: a2390-10.1136\/bmj.a2390.","journal-title":"BMJ"},{"key":"896_CR24","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jama.295.10.1152","volume":"295","author":"G Piaggio","year":"2006","unstructured":"Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ: Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006, 295: 1152-1160. 10.1001\/jama.295.10.1152.","journal-title":"JAMA"},{"key":"896_CR25","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1056\/NEJMcp060423","volume":"355","author":"AJ Schaeffer","year":"2006","unstructured":"Schaeffer AJ: Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med. 2006, 355: 1690-1698. 10.1056\/NEJMcp060423.","journal-title":"N Engl J Med"},{"key":"896_CR26","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1001\/archinte.163.19.2393-b","volume":"163","author":"CM Kunin","year":"2003","unstructured":"Kunin CM: Definition of acute pyelonephritis vs the urosepsis syndrome. Arch Intern Med. 2003, 163: 2393-2394. 10.1001\/archinte.163.19.2393-b.","journal-title":"Arch Intern Med"},{"key":"896_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/BF01973737","volume":"9","author":"T Sandberg","year":"1990","unstructured":"Sandberg T, Englund G, Lincoln K, Nilsson LG: Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. Eur J Clin Microbiol Infect Dis. 1990, 9: 317-323. 10.1007\/BF01973737.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"896_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0149-2918(02)85019-6","volume":"24","author":"CE Cox","year":"2002","unstructured":"Cox CE, Marbury TC, Pittman WG, Brown GL, Auerbach SM, Fox BC, Yang JY: A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis. Clin Ther. 2002, 24: 223-236. 10.1016\/S0149-2918(02)85019-6.","journal-title":"Clin Ther"},{"issue":"Suppl 1","key":"896_CR29","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.ijantimicag.2003.09.002","volume":"23","author":"KG Naber","year":"2004","unstructured":"Naber KG, Bartnicki A, Bischoff W, Hanus M, Milutinovic S, van Belle F, Sch\u00f6nwald S, Weitz P, Ankel-Fuchs D: Gatifloxacin 200 mg or 400 mg once daily is as effective as ciprofloxacin 500 mg twice daily for the treatment of patients with acute pyelonephritis or complicated urinary tract infections. Int J Antimicrob Agents. 2004, 23 (Suppl 1): S41-53. 10.1016\/j.ijantimicag.2003.09.002. S41-S53.","journal-title":"Int J Antimicrob Agents"},{"key":"896_CR30","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1097\/01.ju.0000106191.11936.64","volume":"171","author":"DA Talan","year":"2004","unstructured":"Talan DA, Klimberg IW, Nicolle LE, Song J, Kowalsky SF, Church DA: Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis. J Urol. 2004, 171: 734-739. 10.1097\/01.ju.0000106191.11936.64.","journal-title":"J Urol"},{"key":"896_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","volume":"71","author":"J Peterson","year":"2008","unstructured":"Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB: A Double-Blind, Randomized Comparison of Levofloxacin 750 mg Once-Daily for Five Days With Ciprofloxacin 400\/500 mg Twice-Daily for 10 Days for the Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis. Urology. 2008, 71: 17-22. 10.1016\/j.urology.2007.09.002.","journal-title":"Urology"},{"key":"896_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/0036554021000026988","volume":"35","author":"P Ulleryd","year":"2003","unstructured":"Ulleryd P, Sandberg T: Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis. 2003, 35: 34-39. 10.1080\/0036554021000026988.","journal-title":"Scand J Infect Dis"},{"key":"896_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/BF03084253","volume":"48","author":"KAM van Haaren","year":"2005","unstructured":"van Haaren KAM, Visser HS, van Vliet S, Timmermans AE, Yadava R, Geerlings SE, ter Riet G, van Pinxteren B: NHG-Standaard Urineweginfecties: tweede herziening [Guideline of the Dutch College of General Practitioners on urinary tract infections: second revision]. Huisarts Wet. 2005, 48: 341-352.","journal-title":"Huisarts Wet"},{"key":"896_CR34","unstructured":"Grabe M, Bishop MC, Bjerklund-Johansen TE, Botto H, Cek M, Lobel B, Naber KG, Palou J, Tenke P: Guideline on the management of urinary and male genital tract infections. European Association of Urology. [\n                    http:\/\/www.uroweb.org\/nc\/professional-resources\/guidelines\/online\n                    \n                  ]"},{"key":"896_CR35","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.290.12.1624","volume":"290","author":"SR Tunis","year":"2003","unstructured":"Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003, 290: 1624-1632. 10.1001\/jama.290.12.1624.","journal-title":"JAMA"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-9-131\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-131","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-9-131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T06:52:27Z","timestamp":1548139947000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-9-131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,19]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["896"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-9-131","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,19]]},"article-number":"131"}}